Skip to content

THERALINK TECHNOLOGIES, INC.: 10-K filed 2014-06-13

What THERALINK TECHNOLOGIES, INC. reported in its annual report filed 2014-06-13 (fiscal FY 2014): 21 published measures, 70 facts as tagged in accession 0001062993-14-003701.

This filing

Form
10-K (annual report)
Filed
2014-06-13
Fiscal period
fiscal FY 2014
Accession
0001062993-14-003701 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All THERALINK TECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-02-28349,245USD
At 2013-02-28785,675USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-02-28970,083USD
At 2013-02-28724,110USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-02-28-620,838USD
At 2013-02-2861,565USD
At 2012-02-29245,365USD
At 2011-02-28983,996USD
At 2010-02-28-50,517USD
At 2009-02-28-6,715USD
At 2008-02-29-56,108USD
At 2007-02-28-5,097USD
At 2006-02-28-15,637USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-02-2812,957USD
At 2013-02-28512,484USD
At 2012-02-29258,140USD
At 2005-03-170USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-03-01 to 2014-02-28-757,403USD365
2005-03-18 to 2014-02-28-3,324,667USD3270
2012-03-01 to 2013-02-28-315,938USD365
2011-03-01 to 2012-02-29-952,543USD366
2010-03-01 to 2011-02-28-1,049,087USD365
2009-03-01 to 2010-02-28-58,201USD365
2008-03-01 to 2009-02-28-53,957USD365
2007-03-01 to 2008-02-29-65,411USD366
2006-03-01 to 2007-02-28-50,890USD365
2005-03-19 to 2006-02-28-21,237USD347

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-03-01 to 2014-02-28-372,227USD365
2005-03-18 to 2014-02-28-2,491,608USD3270
2012-03-01 to 2013-02-28-637,621USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-03-01 to 2014-02-2825,000USD365
2005-03-18 to 2014-02-282,710,000USD3270
2012-03-01 to 2013-02-280USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-03-01 to 2014-02-28-152,300USD365
2005-03-18 to 2014-02-28-205,435USD3270
2012-03-01 to 2013-02-28891,965USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-02-28-3,247,667USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2013-03-01 to 2014-02-2862,605,603shares365
2012-03-01 to 2013-02-2862,508,508shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-03-01 to 2014-02-280USD365
2012-03-01 to 2013-02-280USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-03-01 to 2014-02-280USD365
2005-03-18 to 2014-02-28346,050USD3270
2012-03-01 to 2013-02-28132,138USD365
2011-03-01 to 2012-02-29213,912USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-02-2817,885USD
At 2013-02-28535,119USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-03-01 to 2014-02-2831,716USD365
2005-03-18 to 2014-02-2831,716USD3270
2012-03-01 to 2013-02-2845,828USD365

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2013-03-01 to 2014-02-280USD365
2005-03-18 to 2014-02-285,000USD3270
2012-03-01 to 2013-02-280USD365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-03-01 to 2014-02-28534,230USD365
2005-03-18 to 2014-02-28534,230USD3270
2012-03-01 to 2013-02-28323,486USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-02-2862,883,000shares
At 2013-08-0762,508,000shares
At 2013-08-0620,836,000shares
At 2013-02-2862,508,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-02-282,697,541USD
At 2013-02-282,622,578USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2014-02-280USD
At 2013-02-280USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-03-01 to 2014-02-28198,087USD365
2005-03-18 to 2014-02-28198,087USD3270
2012-03-01 to 2013-02-28169,910USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-03-01 to 2014-02-2875,000USD365
2005-03-18 to 2014-02-282,060,000USD3270
2012-03-01 to 2013-02-280USD365

Inspect the source

Entity
THERALINK TECHNOLOGIES, INC. / CIK 0001362703
Captured
SEC response SHA-256
8ea68b29937a9dc79f3f437bfa115ba2d25bc4aa61d4ac37350bf0c10a93ef12

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001362703.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))